New Frontiers in Breast Cancer: Updates and Advances in Treatment

Expert oncologists incorporate personal experience with data from the recent ASCO 2022 annual meeting to highlight optimal testing and management strategies in breast cancer.

EP. 1: Optimizing Breast Cancer Management: Molecular Targets and Platforms for Testing

July 27th 2022

Expert oncologists identify molecular targets in breast cancer and review available testing platforms in the current treatment paradigm.

EP. 2: Next-Generation Sequencing Platforms for Late-Stage HR+ Breast Cancer

July 27th 2022

Shared insight on next-generation sequencing platforms, plasma- and tumor-based, for patients with late-stage HR+ breast cancer.

EP. 3: Adjuvant Olaparib in High-Risk gBRCA1/2 Mutated BC: The OlympiA Trial

August 3rd 2022

Comprehensive insight on trial data from OlympiA, which utilized adjuvant olaparib therapy in patients with gBRCA1/2 mutated breast cancer.

EP. 4: Adjuvant Abemaciclib in High-Risk HR+/HER2-, Node+ BC: The monarchE Trial

August 3rd 2022

Focusing on high-risk HR+/HER2- breast cancer, key opinion leaders review data with adjuvant abemaciclib from the monarchE clinical trial.

EP. 5: KEYNOTE-522: Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in TNBC

August 10th 2022

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.

EP. 6: Utilizing Brain MRI to Inform Treatment for HER2+ Metastatic Breast Cancer

August 10th 2022

A brief review of the value of using brain MRI to help determine treatment approaches for patients with HER2+ metastatic breast cancer.

EP. 7: DESTINY-Breast03: T-DXd in Previously Treated HER2+ Breast Cancer

August 17th 2022

Comprehensive discussion on the DESTINY-Breast03 clinical trial evaluating trastuzumab deruxtecan in patients with previously treated HER2+ metastatic breast cancer.

EP. 8: HER2CLIMB: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

August 17th 2022

Focusing on the HER2CLIMB trial in HER2+ metastatic breast cancer, expert oncologists consider the value of a tucatinib-based regimen in this setting.

EP. 9: DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer

August 24th 2022

Expert perspectives on the use of trastuzumab deruxtecan in HER2-low metastatic breast cancer in the context of the DESTINY-Breast04 trial.

EP. 10: TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Breast Cancer

August 24th 2022

A brief review of data from the TROPiCS-02 clinical trial, which evaluated sacituzumab govitecan in HR+/HER2- metastatic or inoperable breast cancer.